供者IFNL4基因型与急性白血病无关供者清髓性HSCT后非复发死亡率相关
BACKGROUND: The interferon lambda 4 gene (IFNL4) regulates immune responses by controlling the production of IFNλ4, a type III interferon.…
要点
- 供者IFNL4阳性基因型与HSCT后非复发死亡率升高独立相关。
- 受者IFNL4基因型与移植结局无显著关联。
- 优先选择IFNL4-null供者或可降低非复发死亡并改善生存。
核心结论
- 供者IFNL4阳性基因型与接受无关供者清髓性HSCT的急性白血病患者非复发死亡率升高及总生存下降相关。
研究设计与样本
- 两阶段回顾性队列研究,使用CIBMTR数据库,发现队列404例,验证队列1245例,合并分析1593例重叠参与者。
- 纳入2000年1月1日至2008年12月31日期间接受无关10/10 HLA匹配供者清髓性HSCT的急性髓系或急性淋巴细胞白血病患者。
- 发现队列用TaqMan法检测供受者IFNL4多态性(rs368234815、rs12979860、rs117648444),验证队列用Illumina芯片基因型数据。
主要发现
- 受者IFNL4基因型与移植后结局无显著关联。
临床怎么用
- 在无关供者选择中,优先考虑IFNL4-null基因型供者可能降低非复发死亡率并改善总生存,且不显著限制供者库。
- 若研究结果进一步验证,IFNL4基因型可纳入供者选择算法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The interferon lambda 4 gene (IFNL4) regulates immune responses by controlling the production of IFNλ4, a type III interferon. We hypothesised that IFNλ4 could play a role in infection clearance or alloreactivity in patients with acute leukaemia who received a myeloablative 10/10 HLA-matched haematopoietic stem-cell transplantation (HSCT). Therefore, we aimed to assess the association between recipient and donor IFNL4 genotype with post-HSCT survival outcomes in patients with acute leukaemia. METHODS: We did a two-stage retrospective cohort study using the Center for International Blood and Marrow Transplant Research (CIBMTR) repository and database, in which nearly all patients underwent the procedure in the USA. We included patients with acute myeloid leukaemia or acute lymphocytic leukaemia, who received a HSCT at any age from an unrelated 10/10 HLA-matched donor, with a myeloablative conditioning regimen, between Jan 1, 2000, and Dec 31, 2008, and had a pre-HSCT recipient or donor blood sample available. The discovery dataset included patients from an existing National Cancer Institute (NCI) cohort of the CIBMTR database, in which donor and recipient IFNL4 polymorphisms (rs368234815, rs12979860, and rs117648444) were genotyped with TaqMan assays. According to their genotype, donors and recipients were categorised into IFNL4-positive, if they had at least one copy of the allele that supports the production of IFNλ4, or IFNL4-null for the analyses. The findings were independently validated with patients from the DISCOVeRY-BMT cohort (validation dataset) with existing Illumina array genotype data. We also did a combined analysis using data from patients included in both the NCI and DISCOVeRY-BMT cohorts. FINDINGS: We assessed 404 patients (who had a HSCT from Jan 9, 2004, to Dec 26, 2008) in the discovery dataset and 1245 patients in the validation dataset (HSCT Jan 7, 2000, to Dec 26, 2008). The combined analysis included 1593 overlapping participants in both cohorts. Donor, but not recipient IFNL4-positive genotype was associated with increased risk of non-relapse mortality (HR 1·60, 95% CI 1·23-2·10; p=0·0005 in the discovery dataset; 1·22, 1·05-1·40; p=0·0072 in the validation dataset; and 1·27, 1·12-1·45; p=0·0001 in the combined dataset). Associations with post-HSCT overall survival were as follows: HR 1·24, 95% CI 1·02-1·51; p=0·034 in the discovery dataset; 1·10, 0·98-1·20; p=0·10 in the validation dataset; and 1·11, 1·02-1·22; p=0·018 in the combined dataset. INTERPRETATION: Prioritising HSCT donors with the IFNL4-null genotype might decrease non-relapse mortality and improve overall survival without substantially limiting the donor pool. If these findings are validated, IFNL4 genotype could be added to the donor selection algorithm. FUNDING: The National Cancer Institute Intramural Research Program. For full funding list see Acknowledgments.
引用
- Gadalla SM, Wang Y, Wang T, et al. Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study. Lancet Haematol. 2020. PMID: 32976751. doi:10.1016/S2352-3026(20)30294-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。